Chalcogen Bonded Directly To The Five-membered Hetero Ring By Nonionic Bonding Patents (Class 514/424)
Plural chalcogens bonded directly to the five-membered hetero ring by nonionic bonding (Class 514/425)
  • Therapeutic compounds
    Patent number: 7498447
    Abstract: Disclosed herein is a compound having a structure or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: March 3, 2009
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Danny T. Dinh
  • Substituted Pyrrolidine Compounds With Central Nervous System Activity
    Publication number: 20090048329
    Abstract: Provided herein are substituted pyrrolidines that demonstrate binding at biogenic amine transporters and can be synthesized by a methodology based on a chiral dirhodium catalyst. Compositions comprising substituted pyrrolidines can be used to treat central nervous system disorders such as schizophrenia.
    Type: Application
    Filed: June 23, 2008
    Publication date: February 19, 2009
    Inventor: Huw M.L. Davies
  • COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
    Publication number: 20090047243
    Abstract: The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma.
    Type: Application
    Filed: July 17, 2008
    Publication date: February 19, 2009
    Inventors: Richard Rickles, Laura Pierce, Margaret S. Lee
  • Pyrrole-Type compounds, compositions and methods for treating cancer or viral disease
    Patent number: 7491745
    Abstract: The present invention relates to novel Pyrrole-Type compounds, compositions comprising Pyrrole-Type compounds, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a composition comprising a Pyrrole-Type compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell. The present invention also relates to novel Pyrrole-Type compounds, compositions, and methods useful for treating or preventing a viral infection. The compounds, compositions, and methods of the invention are also useful for inhibiting the replication and/or infectivity of a virus.
    Type: Grant
    Filed: October 16, 2006
    Date of Patent: February 17, 2009
    Assignee: Gemin X Pharmaceuticals Canada Inc.
    Inventors: Giorgio Attardo, Roy A. Johnson
  • Blood Pressure Reduction in Salt-Sensitive Hypertension
    Publication number: 20090042951
    Abstract: This invention provides methods and compositions, most preferably pharmaceutical compositions, for treating salt-sensitive hypertension through the inhibition of certain enzymes in the beta-adrenergic pathway that are involved in the regulation of the secretion of water and sodium. These enzymes are cyclic nucleotide phosphodiesterases (PDE) that selectively hydrolyze the second messenger cAMP and, therefore, down-regulate beta-adrenergic signaling. Specifically provided are methods and pharmaceutical compositions for treating salt-sensitive hypertension by inhibiting certain members of the PDE4 family of cyclic nucleotide phosphodiesterases, particularly members of the PDE4B and PDE4D sub-families and, more particularly, the PDE4B1 and PDE4D5 isotypes thereof.
    Type: Application
    Filed: February 22, 2005
    Publication date: February 12, 2009
    Inventor: Robert Danziger
  • 8-AZAPROSTAGLANDIN DERIVATIVE COMPOUND AND AGENT COMPRISING THE COMPOUND AS ACTIVE INGREDIENT
    Publication number: 20090042885
    Abstract: An 8-azaprostaglandin represented by formula (I) (wherein all symbols have the same meanings as described in the specification), a pharmaceutically acceptable salt thereof or a cyclodextrin clathrate thereof.
    Type: Application
    Filed: June 13, 2008
    Publication date: February 12, 2009
    Applicant: Ono Pharmaceutical Co., Ltd.
    Inventors: Kousuke TANI, Kaoru KOBAYASHI, Toru MARUYAMA, Tohru KAMBE, Mikio OGAWA, Tsutomu SHIROYA
  • Muscarinic Receptor Antagonists
    Publication number: 20090042942
    Abstract: The invention provides compounds of formula (I), wherein R1, R2, R3, R4, R5, n and X are as defined in the specification, a process for their preparation, pharmaceutical compositions containing them, a process for preparing pharmaceutical compositions, their use in therapy and intermediates of use in their preparation.
    Type: Application
    Filed: April 18, 2006
    Publication date: February 12, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Andrew Bailey, David Donald
  • CONTROLLED RELEASE TABLET FORMULATIONS FOR THE PREVENTION OF ARRHYTHMIAS
    Publication number: 20090041841
    Abstract: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation are disclosed. Controlled release tablet formulations comprising a therapeutically effective amount of an ion channel modulating compound, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients suitable for controlled release formulations are disclosed. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.
    Type: Application
    Filed: August 1, 2008
    Publication date: February 12, 2009
    Applicant: CARDIOME PHARMA CORP.
    Inventors: Gregory N. Beatch, Alan M. Ezrin
  • METHOD FOR TREATING COLONIC VISCEROSENSITIVITY AND SPASTICITY
    Publication number: 20090036515
    Abstract: There is provided a method of treating colonic viscerosensitivity and spasticity induced by a colonic examination chosen from colonic endoscopy and of barium/air contrast colonic radiography and virtual colonoscopy. The method comprises prescribing and/or administering to a patient in need thereof a pharmaceutically effective oral, sub-lingual, nasal or transdermic dose of a non-centrally-acting opioid agonist for a period of at least two days before the colonic examination.
    Type: Application
    Filed: July 31, 2008
    Publication date: February 5, 2009
    Inventor: Francois MARTIN
  • Therapeutic effects of Bryostatins, Bryologs, and other related substances on Ischemia/stroke-induced memory impairment and brain injury
    Publication number: 20090036514
    Abstract: The invention provides for the use of protein kinase activators or boosters of nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) or other neurotrophic factors to treat stroke. Specifically, the present invention provides methods of treating stroke comprising the steps of identifying a subject having suffered a stroke and administering to said subject an amount of a pharmaceutical composition comprising a protein kinase C (PKC) activator or 4-methylcatechol acetic acid (MCBA) and a pharmaceutically acceptable carrier effective to treat at least one symptom of stroke.
    Type: Application
    Filed: February 11, 2008
    Publication date: February 5, 2009
    Inventors: Miao- Kun Sun, Daniel L. Alkon
  • Inhibitors of TACE
    Patent number: 7485664
    Abstract: The present invention relates to compounds that inhibit TACE, compositions thereof, and methods of using those compounds and compositions for treating diseases.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: February 3, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Upul Bandarage, Jon H. Come, Emanuele Perola, Govinda Rao Bhisetti, Jeffrey O. Saunders, Tiansheng Wang, Shi-Kai Tian
  • Substituted 3-amino-pyrrolidino-4-lactams
    Patent number: 7485641
    Abstract: The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R1, n and R2 are as described herein; compositions thereof; and uses thereof.
    Type: Grant
    Filed: June 18, 2007
    Date of Patent: February 3, 2009
    Assignee: Pfizer, Inc.
    Inventors: David W. Piotrowski, Yu Hui, John W. Benbow
  • Therapeutic agent for diabetes mellitus
    Patent number: 7485662
    Abstract: An object of the present invention is to provide a therapeutic agent for diabetes mellitus or insulin resistance improving agent, or to provide foods and drinks, food and drink additives, and feeds or feed additives for treating diabetes mellitus or improving insulin diabetes. In order to achieve such an object, the present invention provides a therapeutic agent for diabetes mellitus and insulin resistance improving agent comprising hydroxyproline, a hydroxyproline derivative or a pharmaceutically acceptable salt thereof or foods and drinks, food and drink additives, feeds or feed additives for treatment of diabetes mellitus or improvement of insulin resistance comprising the same.
    Type: Grant
    Filed: March 19, 2004
    Date of Patent: February 3, 2009
    Assignee: Kyowa Hakko Kogyo Co., Ltd.
    Inventors: Toshikazu Kamiya, Akio Shirai, Miho Takada, Fumiko Ogino
  • Therapeutic lactams
    Patent number: 7482475
    Abstract: Disclosed herein is a compound having a structure Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
    Type: Grant
    Filed: August 9, 2007
    Date of Patent: January 27, 2009
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Robert M. Burk
  • Agent or method for treating severe aphasia in cerebrovascular accident chronic stage
    Patent number: 7479506
    Abstract: The present invention relates to a method for treating a patient having suffered from severe aphasia associated with cerebrovascular accident chronic stage for at least three years, wherein said treatment consists essentially of administering a composition comprising 2-oxo-1-pyrrolidineacetamide as an active ingredient and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 24, 2004
    Date of Patent: January 20, 2009
    Inventor: Hideki Ohyama
  • Substituted gamma lactams as therapeutic agents
    Patent number: 7476747
    Abstract: A compound comprising or a pharmaceutically acceptable salt, prodrug, or a metabolite thereof is disclosed herein. Y, A, and B are as described herein. Methods, compositions, and medicaments related to these compounds are also disclosed.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: January 13, 2009
    Assignee: Allergan, Inc.
    Inventors: David W. Old, Danny T. Dinh
  • Synthesis of N-heterocycles, beta-amino acids, and allyl amines via aza-payne mediated reaction of ylides and hydroxy aziridines
    Publication number: 20090012120
    Abstract: An ylide-based aza-Payne rearrangement of 2,3-aziridin-1-ols leads to an efficient process for the preparation of pyrrolidines. The aza-Payne rearrangement under the basic reaction conditions favors the formation of epoxy amines. Subsequent nucleophilic attack of the epoxide by the ylide yields a bis-anion, which upon a 5-exo-tet ring closure yields the desired pyrrolidine, thus completing the relay of the 3-membered the 5-membered nitrogen containing ring system. This process takes place with complete transfer of stereochemical fidelity, and can be applied to sterically hindered aziridinols.
    Type: Application
    Filed: May 9, 2007
    Publication date: January 8, 2009
    Applicant: Board of Trustees of Michigan State University
    Inventors: Babak Borhan, Jennifer M. Schomaker, Somnath Bhattacharjee, Keith Korthals
  • Cosmetic Compositions
    Publication number: 20090010863
    Abstract: There is disclosed a skincare composition suitable for topical application to the skin. The composition comprises two or more active ingredients selected from the group consisting of a) dipalmitoyl hydroxyproline, salts and esters thereof; b) carnitine; and c) an extract of Haematococcus pluvialis. Compositions prepared in accordance with the invention are useful for improving the appearance of the skin.
    Type: Application
    Filed: October 13, 2005
    Publication date: January 8, 2009
    Applicant: The Boots Company PLC
    Inventors: Stephen Peter Barton, Stewart Paul Long, Lloyd George Hamilton
  • Organic Compounds Comprising a Glycopyrrolium Salt
    Publication number: 20080317862
    Abstract: Medicaments comprising (A) an antimuscarinic agent and (B) a corticosteroid for the treatment of inflammatory or obstructive airways diseases.
    Type: Application
    Filed: November 20, 2006
    Publication date: December 25, 2008
    Inventors: Stephen Paul Collingwood, Barbara Haeberlin
  • TRANSDERMAL DELIVERY SYSTEM COMPRISING GLYCOPYRROLATE TO TREAT SIALORRHEA
    Publication number: 20080317832
    Abstract: In one aspect, the invention includes a method for treating sialorrhea, comprising the steps of identifying a patient afflicted with sialorrhea and administering a therapeutically effective amount of glycopyrrolate to the patient using a transdermal route of administration. In another aspect, the invention is a transdermal drug delivery system for treating a patient exhibiting sialorrhea, including a transdermal patch, a therapeutically effective amount of glycopyrrolate contained in the transdermal patch to alleviate sialorrhea, and a pharmaceutically acceptable carrier. The transdermal patch can be a single layer drug-in-adhesive patch, a multi-layer drug-in-adhesive patch, a matrix patch, or a reservoir patch.
    Type: Application
    Filed: June 23, 2008
    Publication date: December 25, 2008
    Applicant: Sciele Pharma, Inc.
    Inventor: LARRY DILLAHA
  • CONTROLLED RELEASE ORAL FORMULATIONS OF ION CHANNEL MODULATING COMPOUNDS AND RELATED METHODS FOR PREVENTING ARRHYTHMIA
    Publication number: 20080312309
    Abstract: The present invention provides methods of treating and preventing arrhythmia and other diseases or disorders, using ion channel modulating compounds, including vernakalant hydrochloride. The present invention further provides controlled release oral formulations and dosages of vernakalant hydrochloride, which are effective in preventing arrhythmia. Certain methods and formulations of the present invention are adapted for the treatment and prevention of arrhythmia and other disease or disorders in subjects identified as having altered drug metabolism due to polymorphism of the gene encoding cytochrome P450 2D6.
    Type: Application
    Filed: May 2, 2008
    Publication date: December 18, 2008
    Applicant: CARDIOME PHARMA CORP.
    Inventors: Jeffery J. Wheeler, Gregory N. Beatch
  • Inhibitors against activation of NF-kappaB
    Publication number: 20080311074
    Abstract: A method of inhibiting NF-?B activation in a mammal including a human, which comprises the step of administering an effective dose of a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:
    Type: Application
    Filed: April 11, 2008
    Publication date: December 18, 2008
    Applicant: INSTITUTE OF MEDICAL MOLECULAR DESIGN INC.
    Inventors: Susumu MUTO, Akiko ITAI
  • 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
    Patent number: 7465751
    Abstract: This invention generally relates to the derivatives of 1-substituted-3-pyrroli dines having the structure of Formula (I): The compounds of this invention can function as muscarinic receptor antagonists, and can be used for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to a process for the preparation of the compounds of the present invention. pharmaceutical compositions containing the compounds of the present invention and the methods for treating the diseases mediated through muscarinic receptors.
    Type: Grant
    Filed: December 23, 2002
    Date of Patent: December 16, 2008
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Anita Mehta, Jang Bahadur Gupta, Pakala Kumara Savithru Sarma
  • 1,4-Bis-N-Oxide-5,8- Dihydroxyanthracenedione Compounds and the Use Thereof
    Publication number: 20080305082
    Abstract: Disclosed are compounds having Formula I: and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, A, and B are as defined herein, for use in methods for treating, preventing or ameliorating hyperproliferative disorders, such as cancer and other diseases and conditions. The invention also relates to pharmaceutical compositions and formulations comprising a compound having Formula I, and in combination with one or more other active agents and/or treatments.
    Type: Application
    Filed: September 14, 2005
    Publication date: December 11, 2008
    Inventors: John G. Curd, Robert L. Capizzi, John F.W. Keana
  • Peptide-like compounds that inhibit coronaviral 3CL and flaviviridae viral proteases
    Patent number: 7462594
    Abstract: This invention relates to treating an infection with a virus using protease inhibitors. Examples of the protease inhibitors include compounds of formula (II). Each variable is defined in the specification.
    Type: Grant
    Filed: February 25, 2005
    Date of Patent: December 9, 2008
    Assignee: Taigen Biotechnology Co., Ltd.
    Inventors: Syaulan Yang, Jen-Dar Wu, Feng-Yih Su, Chun-Wei Kuo, Wen-Chang Chen, Ming-Chu Hsu, Yibin Xiang, Ching-Cheng Wang, Shao-Ying Liao
  • Medicaments For Inhalation Comprising Pde IV Inhibitors and Enantiomerically Pure Glycopyrrolate Salts
    Publication number: 20080292562
    Abstract: The present invention relates to novel pharmaceutical compositions based on PDE IV inhibitors (2) and salts of formula (1) wherein X may have the meanings defined in the description and claims, and their use in the treatment of respiratory complaints.
    Type: Application
    Filed: June 13, 2005
    Publication date: November 27, 2008
    Inventors: Michael P. Pieper, Michel Pairet
  • Benzyloxy derivatives
    Patent number: 7456210
    Abstract: The present invention relates to compounds of formula I wherein R1 and R2 are as defined in the specification and to pharmaceutically acceptable salts thereof for the treatment of diseases, which are mediated by monoamine oxidase B inhibitors, for example Alzheimer's disease and senile dementia.
    Type: Grant
    Filed: July 27, 2005
    Date of Patent: November 25, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Rosa Maria Rodriguez-Sarmiento, Wolfgang Wostl, Rene Wyler
  • Peptide deformylase inhibitors
    Patent number: 7456211
    Abstract: The present invention involves novel anti-bacterial compounds represented by Formula (I), pharmaceutical compositions thereof, their use as PDF inhibitors, and their use in the treatment of bacterial infections.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: November 25, 2008
    Assignee: SmithKline Beecham Corp
    Inventors: Kelly M. Aubart, Jia-Ning Xiang, Siegfried B. Christensen, IV, Xiangmin Liao, Maxwell D. Cummings
  • BENZYLATED PDE4 INHIBITORS
    Publication number: 20080287522
    Abstract: The present invention is directed to a method for reducing the emetogenic effects of PDE inhibitors, and more particularly is directed to compounds having PDE4 inhibition activity with little or no emetogenic side-effects, and chemical methods including benzylation for preparing such compounds. A benzyl group may be attached to either a carbon or nitrogen atom of a PDE4 inhibitor. Suitable benzylation chemistry is to extract a hydrogen from a PDE4 inhibitor, preferably with a base, and then react the resulting nucleophilic PDE4 inhibitor with a benzylating agent, e.g., benzyl bromide or a derivative thereof.
    Type: Application
    Filed: July 21, 2008
    Publication date: November 20, 2008
    Applicant: BIOLIPOX AB
    Inventors: Ronald W. Lauener, David L. Burgoyne, Patrick J. Rebstein, Lloyd F. Mackenzie, Yuanlin Zhou, Yaping Shen
  • Phenyl-Substituted Pyrrolidones
    Publication number: 20080287516
    Abstract: The present invention relates to phenyl-substituted pyrrolidones and compounds related to phenyl-substituted pyrrolidones. One use of these compounds is for the inhibition of viruses, e.g., HIV. The invention further relates to methods of malting these compounds, methods of identifying the efficacy of these compounds, and methods of using these compounds to inhibit or prevent HIV infection and related disease states such as AIDS.
    Type: Application
    Filed: January 30, 2006
    Publication date: November 20, 2008
    Applicant: IRM LLC
    Inventors: Baogen Wu, Truc Ngoc Nguyen, David Archer Ellis, Xiaohui He, Beth Marie Anaclerio, Kunyong Yang, Ha-soon Choi, Zhicheng Wang, Thomas H. Marsilje, Yun He
  • Cycloalkyl Lactam Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase 1
    Publication number: 20080275043
    Abstract: The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Fomula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia.
    Type: Application
    Filed: October 26, 2005
    Publication date: November 6, 2008
    Inventors: Thomas Daniel Aicher, Mark Joseph Chicarelli, Ronald Jay Hinklin, Hongqi Tian, Owen Brendan Wallace, John Gordon Allen, Zhaogen Chen, Thomas Edward Mabry, Jefferson Ray McCowan, Nancy June Snyder, Leonard Larry Winneroski
  • Pharmaceutical Compositions Comprising Levetiracetam and Process for Their Preparation
    Publication number: 20080269316
    Abstract: The present invention relates to a pharmaceutical composition comprising levetiracetam as active ingredient and 2.0 to 9.0% per weight of disintegrant, 0.0 to 3.0% per weight of gliding agent, 0.5 to 6.0% per weight of binder, and 0.0 to 1.0% per weight of lubricant, with respect to the total weight of the pharmaceutical composition, and to a process for its preparation.
    Type: Application
    Filed: July 24, 2006
    Publication date: October 30, 2008
    Applicant: UCB PHARMA, S.A.
    Inventors: Michel Deleers, Jean-Benoit Hubert
  • ORALLY DISINTEGRATING TABLET COMPRISING GLYCOPYRROLATE FOR TREATING SIALORRHEA
    Publication number: 20080260823
    Abstract: The invention provides an orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate for treating sialorrhea, as well as a kit comprising the orally disintegrating tablet, prescribing information, and a container. The invention also provides a method of treating sialorrhea in a patient comprising administering the orally disintegrating tablet comprising a therapeutically effective amount of glycopyrrolate to the patient.
    Type: Application
    Filed: April 20, 2007
    Publication date: October 23, 2008
    Applicant: Sciele Pharma, Inc.
    Inventor: Larry Dillaha
  • PHARMACEUTICALLY ACTIVE BENZSULFONAMIDE DERIVATIVES AS INHIBITORS OF PROTEIN JUNKINASES
    Publication number: 20080255222
    Abstract: The present invention relates to benzsulfonamide derivatives of formula I and methods of use thereof. The benzsulfonamide derivatives of the present invention are efficient modulators of the JNK pathway. In particular the benzsulfonamide derivatives of the present invention are selective inhibitors of JNK 2 and 3.
    Type: Application
    Filed: June 19, 2008
    Publication date: October 16, 2008
    Applicant: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.
    Inventors: Serge HALAZY, Dennis Church, Stephen J. Arkinstall, Marco Biamonte, Montserrat Camps, Jean-Pierre Gotteland, Thomas Rueckle
  • PYRROLIDONES WITH ANTI-HIV ACTIVITY
    Publication number: 20080255136
    Abstract: The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS.
    Type: Application
    Filed: April 22, 2008
    Publication date: October 16, 2008
    Applicant: IRM LLC
    Inventors: Baogen Wu, Yun He, Truc Nguyen, Kelli L. Kuhen, David Archer Ellis, Tao Jiang, Xiaohui He, Kunyong Yang, Badry Bursulaya
  • Therapeutic Substituted Gamma Lactams
    Publication number: 20080255220
    Abstract: Disclosed herein is a compound comprising or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, X, R and D are as described. Methods, compositions, and medicaments related thereto are also disclosed.
    Type: Application
    Filed: June 6, 2006
    Publication date: October 16, 2008
    Applicant: ALLERGAN, INC.
    Inventor: David W. Old
  • KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT AND ALTERNATING IRRITABLE BOWEL SYNDROME
    Publication number: 20080242720
    Abstract: The present invention concerns methods useful in treating one or more subtypes of irritable bowel syndrome (IBS), or useful in treating diarrhea. The invention relates to the use of peripherally selective kappa-opiate agonists, especially N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and/or a pharmaceutically acceptable salt thereof for treating a subject having diarrhea-predominant IBS (IBS-D) or IBS with alternating diarrhea and constipation (IBS-A), or a subject having diarrhea.
    Type: Application
    Filed: March 7, 2008
    Publication date: October 2, 2008
    Inventor: Allen MANGEL
  • Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist
    Publication number: 20080234337
    Abstract: The present invention relates to a preventive and/or therapeutic agent for hyperkalemia, and a potassium excretion promoter containing EP4 agonist. Since EP4 agonist promotes potassium excretion, it is useful as a preventive and/or therapeutic agent for hyperkalemia. In addition, if selective EP4 agonist uses, it is a preventive and/or therapeutic agent for hyperkalemia without side effects. Further, if EP4 agonist is used, it is useful as improving agent for various symptoms (e.g. paresthesia, error of perception, weakness, myoparalysis, nausea, vomit, abdominal pain, diarrhea, arrhythmia, atrioventricular block, ventricular fibrillation, atrial fibrillation, cardiac arrest, asphyxia and/or dyspnoea etc.).
    Type: Application
    Filed: August 9, 2005
    Publication date: September 25, 2008
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Atsukazu Kuwahara, Yuichi Suzuki, Takayuki Maruyama
  • DERIVATIVES OF ASIMADOLINE WITH COVALENTLY BONDED ACIDS
    Publication number: 20080234209
    Abstract: The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the pharmaceutical composition.
    Type: Application
    Filed: June 2, 2008
    Publication date: September 25, 2008
    Inventors: Matthias WIESNER, Christoph SEYFRIED
  • Assays
    Publication number: 20080227848
    Abstract: A method of identifying an agent which modulates 2-oxoglutarate dependent oxygenase activity, the method comprising contacting a 2-oxoglutarate dependent oxygenase and a test agent in the presence of a substrate comprising one or more ankyrin repeat, or fragment thereof, in conditions under which the substrate is hydroxylated in the absence of the test agent; and determining hydroxylation of the substrate.
    Type: Application
    Filed: March 24, 2005
    Publication date: September 18, 2008
    Applicant: Isis Innovation Limited
    Inventors: Christopher Joseph Schofield, Kirsty Sarah Hewitson, Michael Arnold McDonough, Peter John Ratcliffe, Norma Masson, Matthew Edward Cockman
  • Orally Disintegrable Solid Preparation Comprising Povidone-Iodine
    Publication number: 20080227849
    Abstract: An orally disintegratable solid preparation comprising povidone-iodine as an active ingredient, which is obtained by direct powder compression of a mixture containing a granular sugar alcohol and povidone-iodine, wherein the mixture does not contain a basic ingredient and is not subjected to wet granulation. High quality solid preparation as an orally disintegratable preparation comprising povidone-iodine, which have a constant content of povidone-iodine per a single unit solid preparation and maintain stability of iodine, are provided.
    Type: Application
    Filed: December 26, 2005
    Publication date: September 18, 2008
    Applicant: KOWA COMPANY, LTD.
    Inventors: Yuichiro Kano, Hiroaki Kuga, Shigehiro Maetani
  • Spirocyclic 3-phenyl-3-substituted 4-ketolactams and 4-ketolactones
    Patent number: 7425575
    Abstract: The present invention relates to novel phenyl-substituted 4-ketolactams and -lactones of the formula (I) in which A, B, Q, G, W, X, Y, Z and R3 are as defined above, to processes and intermediates for their preparation and to their use as pesticides, microbicides and herbicides.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: September 16, 2008
    Assignee: Bayer CropScience AG
    Inventors: Reiner Fischer, Astrid Ullmann, Thomas Bretschneider, Mark Wilhelm Drewes, Angelika Lubos-Erdelen, legal representative, Dieter Feucht, Udo Reckmann, Christoph Erdelen
  • The Treatment of Respiratory Diseases
    Publication number: 20080220073
    Abstract: A pharmaceutical composition for pulmonary delivery comprises glycopyrrolate in a controlled release formulation, wherein, on administration, the glycopyrrolate exerts its pharmacological effect over a period greater than 12 hours.
    Type: Application
    Filed: March 14, 2008
    Publication date: September 11, 2008
    Inventors: Robin Mark Bannister, Andrew John McGlashan Richards, Julian Clive Gilbert, David A. V. Morton, John Staniforth
  • Cycloalkyl Lactam Derivatives As Inhibitors Of 11-Beta-Hydroxysteroid Dehydrogenase 1
    Publication number: 20080214621
    Abstract: The present invention provides compounds of formula I that are useful as potent and selective inhibitors of 11-beta hydroxysteroid dehydrogenase 1. The present invention further provides a pharmaceutical composition which comprises a compound of Formula I, or a pharmaceutical salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. In addition, the present invention compositions containing these compounds for the treatment of metabolic syndrome, diabetes, hyperglycemia obesity, hypertension, hyperlipidemia, other symptoms associated with hyperglycemia, and related disorders. Formula I wherein G1 is methylene or ethylene; L is —(C1-C4)alkylene-, —S—, —CH(OH)—, or —O—; R0 is Formula II or Formula III and the other substituents are as defined in the claims.
    Type: Application
    Filed: December 16, 2005
    Publication date: September 4, 2008
    Inventors: Thomas Daniel Aicher, Mark Joseph Chicarelli, Cassandra A. Gauthier, Ronald Jay Hinklin, Hongqi Tian, Owen Brendan Wallace, Alexei Pavlovych Krasutsky, John Gordon Allen
  • Methods and Systems for Treating Asthma and Other Respiratory Diseases
    Publication number: 20080213248
    Abstract: The subject invention provides methods for using TRPM8 receptors as a therapeutic target for identifying effective methods or compounds useful in the diagnosis or treatment of respiratory diseases or conditions. In certain embodiments, compositions that are identified using the methods of the invention are administered to a patient to diagnose or treat a respiratory disease or condition. In a preferred embodiment, TRPM8 receptor blockers are identified and administered, in accordance with the subject invention, to treat a patient with a respiratory disease, such as asthma.
    Type: Application
    Filed: September 2, 2005
    Publication date: September 4, 2008
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventor: Jianguo G. Gu
  • Gamma lactams as prostaglandin agonists and use thereof
    Patent number: 7419999
    Abstract: 1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.
    Type: Grant
    Filed: June 9, 2003
    Date of Patent: September 2, 2008
    Assignee: Applied Research Systems ARS Holding N.V.
    Inventors: Gian Luca Araldi, Adulla P. Reddy, Zhong Zhao, Sean D. McKenna, Bagna Bao
  • Peptide Deformylase (Pdf) Inhibitors 4
    Publication number: 20080207686
    Abstract: The present invention relates to compounds of formula (I). These compounds are a novel type of peptide deformylase (PDF) inhibitors, and are therefore of great interest especially as new antibiotics.
    Type: Application
    Filed: June 6, 2006
    Publication date: August 28, 2008
    Inventor: Michael Thormann
  • Methods of treatment with selective EP4 receptor agonists
    Patent number: 7414071
    Abstract: The present invention provides a method of treating hypertension, liver failure, loss of patency of ductus arteriosus, glaucoma or ocular hypertension in a patient, comprising administering to the patient a therapeutically effective amount of a selective EP4 receptor agonist of Formula I or a prodrug thereof, a pharmaceutically acceptable salt of the selective EP4 receptor agonist or prodrug or a stereoisomer or diastereomeric mixture of the EP4 receptor agonist, prodrug or salt, wherein the variables X, Z, Q, , and R2 are as defined in the specification.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: August 19, 2008
    Assignee: Pfizer Inc.
    Inventors: Kimberly O. Cameron, Bruce A. Lefker, Delvin R. Knight, Jr.
  • Substituted heterocycles, their use as medicament, and pharmaceutical preparations comprising them
    Publication number: 20080188520
    Abstract: The invention relates to compounds of formula I in which A, R1, R2, R3, R4, R5, R6, R7 and n have the meanings stated in the claims. The compounds are particularly suitable as antiarrhythmic active ingredients, in particular for the treatment and prophylaxis of atrial arrhythmias, for example atrial fibrillation (AF) or atrial flutter.
    Type: Application
    Filed: December 12, 2007
    Publication date: August 7, 2008
    Applicant: SANOFI-AVENTIS
    Inventors: Joachim BRENDEL, Heinrich Christian ENGLERT, Stefan PEUKERT, Klaus WIRTH, Michael WAGNER, Jean-Marie RUXER, Fabienne PILORGE
  • USES OF ION CHANNEL MODULATING COMPOUNDS
    Publication number: 20080188547
    Abstract: Methods, formulations, dosing regimes, and routes of administration for the treatment or prevention of arrhythmias, including the treatment or prevention of atrial fibrillation. In these methods, the disease or condition is treated or prevented by administering one or more ion channel modulating compounds to a subject, where the ion channel modulating compound or compounds produce specific plasma levels in the subject. The ion channel modulating compounds may be cycloalkylamine ether compounds, particularly cyclohexylamine ether compounds.
    Type: Application
    Filed: November 29, 2007
    Publication date: August 7, 2008
    Applicant: CARDIOME PHARMA CORP.
    Inventors: Gregory N. Beatch, Alan M. Ezrin